Last updated on October 2009

A Phase 3 Study Comparing 2 Doses of study drug vs. Placebo for Treatment of Rheumatoid Arthritis


Brief description of study

A Phase 3 Study Comparing 2 Doses of study drug vs. Placebo for Treatment of Rheumatoid Arthritis

Detailed Study Description

This Phase 3 study is intended to provide evidnece of the efficacy and safety of study drug when dosed twice a day in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of study drug in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.

Patient Inclusion Criteria:

  • The patient has a diagnosis of RA.
  • The patient has active disease at the onset of the study.
  • Patient had an inadequate response to current RA medicine.

Patient Exclusion Criteria:

  • Patient does not have cancer.
  • Patient does not have a history of infection requiring hospitalization within the 6 months prior to the first dose of study drug.

Clinical Study Identifier: TX134569

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Suzi DeFiesta

CSI Research Inc
Alpharetta, GA USA
  Connect »